S-BIOmedic

“The experience of the JLINX management team is a great support in strategy planning,

fundraising, networking and partnering” Veronika Oudova – CEO S-Biomedic

S-BIOMEDIC Company Profile

S-Biomedic is a Belgium based life science company exploring the unexploited cosmetic and therapeutic potential of the skin microbiome. The skin microbiome – a habitat of billions of beneficial and harmful bacteria- contributes to a healthy skin. An imbalance of these bacteria can lead to a variety of skin problems including acne, eczema, rosacea and ageing. In this context, the skin microbiome offers unparalleled skincare and clinical opportunities for a wide range of unmet medical

conditions. This represents a unique opportunity for the commercial development of break-through cosmetic and dermatological products.

Following the great success in the gut microbiome field, skin is rapidly becoming the main target of microbiome research. Thanks to new sequencing methods we can identify more and more links between the microbiome and chronical skin problems.

Background

The start of S-Biomedic goes back to 2014 when co-founders Veronika Oudova, Bernhard Paetzold and Marc Guell were awarded a grant from ‘Start-Up Chile’ allowing them to generate the necessary proof-of-concept data for a breakthrough idea on ‘Designing bacteria as living pills’. At the end of this internationally acclaimed one year Start-up Accelerator programme, S-Biomedic was ready to file a 1st Patent for a targeted microbiome modulation technology enabling to transplant beneficial bacteria on the skin.

After successively having won the 1st prize Healthcare & Biotech at the European start-up competition South Summit 2015 in Madrid and finishing amongst the Top-10 Finalists at OneStart Biotech Europe in 2016, early 2017 S-Biomedic joined Johnson & Johnson Innovation’s JLINX initiative. This multifaceted incubation model enables S-Biomedic to accelerate the further development of its first acne-zapping product and complete the required clinical studies by 2019 through venture financing and direct access to both J&J’s consumer skin care expertise and Janssen’s global R&D expertise.

Technology

S-Biomedic uses a targeted microbiome modulation-based technology to recover a healthy skin.

In the case of acne vulgaris, a unique pathogenicity biomarker is used to detect harmful bacteria. After removing these pathogenic microbiome strains, well-targeted consortia of good bacteria are being introduced giving them an advantage to colonize and grow. Diversity of beneficial bacteria is key to restore a well-balanced skin microbiome, resulting in a more stable environment.

What makes S-Biomedic’s technology truly unique is that the bacteria found in their product are sourced directly from healthy human skin, offering a ready-made natural cocktail of different strains already well adapted to the skin microbiome. This ensures that beneficial microbes colonize the skin in the most efficient and effective way possible. This is very different from traditional acne treatment whereby a ‘big blast’ is applied to fight acne but which ends up pushing the skin’s microbiome from one imbalance into another one.

S-Biomedic owns all IP on its unique pathogenicity bio-marker and bacterial compositions.

2

S-BIOmedic

S-BIOMEDIC Company Profile

Pipeline-Products

S-Biomedic’s product pipeline is based on the use of our natural skin bacteria for cosmetics applications, and eventually for therapeutic solutions in a second phase.

The lead program is acne vulgaris for which first clinical in vivo studies are complementing the positive in vitro test data. Large cohort clinical studies are scheduled to be completed by early 2019.

Simultaneously, S-Biomedic initiated the early stage concept development of two more skin care programmes in the ageing and dandruff domains.

Pipeline skin careConceptdevelopment

In vitro development

Clinical development Prototype Partner

Acne

Ageing

Dandruff

S-BIOMEDIC Company Profile

3

Why JLINX The JLINX incubation model offers S-Biomedic a unique combination of expertise in the fields of start-up funding, scientific research, lab facilities and business management

Thanks to its venture syndication expertise, Bioqube guided S-Biomedic to secure seed financing led by Johnson & Johnson Innovation – JJDC, inc and supported by CG Health Ventures.

Via the close link with the Human Microbiome Institute and direct access to the Janssen R&D site and the vast global J&J Consumer network, JLINX offers excellent scientific support, regulatory advice, clinical study design support

etc. Cross-fertilization with other JLINX residents, especially those into microbiome, offers invaluable advantage in terms of knowledge sharing and speeding up solutions.

JLINX hosts a dedicated microbiome lab offering ultra-performing equipment such as a state-of-the art colony picker and liquid handling machine, all unaffordable for early-stage start-ups.

Through the involvement of Bioqube, JLINX offers expert guidance in developing business plans and investment plans.

S-BIOmedic

Veronika Oudova, CEO, Co-founder

Master in Management & Trade Over 9 years of management and business experience

Bernhard Paetzold CSO, Co-founder

PhD in synthetic biology,Pioneer in designing bacteria as living pills

Marc Guell Director, Co-founder

Tenure track Professor at Pompeu Fabra University (Spain)Expert in genome synthesis, genome analysis and CRISPR gene editing

Carlos Gallardo Director

Managing Director CG Health Ventures, over 15 years experience in Pharma, licensing, Business Development and acquisitions

Team

Nico Vandervelpen Director

Managing partner Bioqube Venture, Over 20 years experience in Venture Capital and M&A, Board member in various biotech companies

S-BIOmedic

S-BIOMEDIC Company Profile

4

Highlights

2014 Proof of concept grant Start-up Chile

2015 Proprietary Microbiome Modulation Technology patent

3 year EU funding agreement (2015-2018)

2016Top 10 finalist at OneStart Biotech Europe

2017 JLINX membership – J&J Innovation Funding supported by CG Health Ventures

Future

2019 Large cohort clinical study on a cosmetic product for acne patients

2020 Market launch of a cosmetic product for acne patients

Prof. Dr. Harald Gollnick Key Opinion Leader in acne vulgaris

Prof. Luis Serrano Director of Center for Genomic Regulation Barcelona; Leading Research expert in synthetic biology

Prof. Toni Gabaldon ICREA Research Professor with expertise in genomics and bioinformatics

Advisors & Partners

Prof. Dirk Gevers Global Head of the Janssen Human Microbiome Institute

S-BIOMEDIC Company ProfileS-BIOmedic

5

Contact S-Biomedic

Veronika Oudova

email: veronika.oudova@sbiomedic.com

phone: +32 477 269940

www.sbiomedic.com

Headquarters:

S-Biomedic NV

Janssen Research Campus / JLINX

Turnhoutseweg 30

2340 Beerse, Belgium

S-BIOmedic

supported by: